LUTATHERA Novartis Pharmaceuticals Australia Pty Ltd

Product name

LUTATHERA

Accepted date

Sep-2024

Active ingredients

lutetium (177Lu) oxodotreotide

Proposed indication

Treatment of somatostatin receptor-positive
gastroenteropancreatic neuroendocrine tumours in adults.

Application type

A (new medicine)

Publication date

Sep-2024

Help us improve the Therapeutic Goods Administration site